Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 13
Submit an article Journal homepage
130
Views
5
CrossRef citations to date
0
Altmetric
Reviews

Postmenopausal hormone therapy and the risk of cardiovascular disease

Vera Bittner University of Alabama at Birmingham, Division of Cardiovascular Disease, 701 19th Street South – LHRB 310, Birmingham, Alabama 35294-0007, USA +1 205 934 7336; +1 205 975 6237; [email protected]
, MD MSPH
Pages 2041-2053 | Published online: 30 Jun 2009

Bibliography

  • Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:1481-501
  • Stramba-Badiale M, Fox KM, Priori SG, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006;27:994-1005
  • ACOG Committee on Gynecologic Practice. ACOG Committee Opinion 420 November 2008: hormone therapy and heart disease. Obstet Gynecol 2008;112:1189-92
  • Utian WH, Archer DF, Bachmann GA, et al.; North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society. Menopause 2008;15:584-602
  • Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J 2007;28:2028-40
  • Practice Committee of the American Society for Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. Fertil Steril 2008;90(Suppl 3):S88-102
  • American Association of Clinical Endocrinologists Reproductive Medicine Committee. Position Statement on Hormone Replacement Therapy (HRT) and Cardiovascular Risk. The First Messenger 2008; January/February: page 6. Also Available from: http://www.aace.com/pub/pdf/guidelines/HRTCVRISK position_statement.pdf [Last accessed 16 March 2009]
  • Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7
  • Miller AP, Xing D, Feng W, et al. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 2007;14:251-60
  • Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007;14:373-84
  • Stampfer MJ, Coldlitz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63
  • Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37
  • Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72
  • Humphrey LL, Chan BKS, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84
  • Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy. Scientific Review. JAMA 2002;288:872-81
  • Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-50
  • Canonico M, Plu-Bureau G, Lowe GDO, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-31
  • Paganini-Hill A. Hormone replacement therapy and stroke: risk, protection or no effect? Maturitas 2001;38:243-61
  • Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199-208
  • Shlipak MG, Chaput LA, Vittinghoff E, et al.; for the Heart and Estrogen/progestin Replacement Study (HERS) Investigators. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). Am Heart J 2003;146:870-5
  • Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-52
  • The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 2004;291:1701-12
  • Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-33
  • Wakatsuki A, Ikenoue N, Okatani Y, Fukaya T. Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol 2001;37:425-30
  • Hsia J, Otvos JD, Rossouw JE, et al. Lipoprotein particle concentrations may explain the absence of coronary protection in the Women's Health Initiative Hormone Trials. Arterioscler Thromb Vasc Biol 2008;28:1666-71
  • Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 2001;75:898-915
  • Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative Trials of Hormone Therapy. Arch Intern Med 2008;168:2245-53
  • Koh KK, Yoon BK. Controversies regarding hormone therapy: insights from inflammation and hemostasis. Cardiovasc Res 2006;70:22-30
  • Lakoski SG, Herrington DM. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Climacteric 2005;8:317-26
  • Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system. Lessons learned and unanswered questions. J Am Coll Cardiol 2006;47:1741-53
  • Vigen C, Hodis HN, Chandler WL, et al. Postmenopausal oral estrogen therapy affects hemostatic factors, but does not account for reduction in the progression of subclinical atherosclerosis. J Thromb Haemost 2007;5:1201-8
  • Angerer P, Stork S, Kothny W, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-8
  • Byington RP, Furberg CD, Herrington DM, et al. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 2002;22:1692-7
  • Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53
  • Espeland MA, Applegate W, Furberg CD, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Am J Epidemiol 1995;142:1011-19
  • Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9
  • Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40
  • Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-45
  • Ouyang P, Tardif JC, Herrington DM, et al.; for the EAGAR investigators. Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis 2006;189:375-86
  • Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
  • Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57
  • Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study. Lessons learned. Circulation 2002;105:917-22
  • Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-42
  • Hsia J, Simon JA, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease. The Heart and Estrogen/Progestin Replacement Study. Circulation 2000;102:2228-32
  • Grady D, Wenger NK, Herrington DM, et al. for the Heart and Estrogen/progestin Replacement Study Research Group. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689-96
  • Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002;22:1012-17
  • Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002;109:1056-62
  • Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9
  • Hsia J, Langer RD, Manson JAE, et al. Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. Arch Intern Med 2006;166:357-65
  • Manson JAE, Allison MA, Rossouw JE, et al.; for the WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-602
  • Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425-34
  • Hsia J, Criqui MH, Herrington DM, et al. Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. Am Heart J 2006;152:170-6
  • Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-80
  • Manson JAE, Hsia J, Johnson KC, et al.; for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
  • Wassertheil-Smoller S, Hendrix SL, Limacher M, et al.; for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84
  • Cushman M, Kuller LH, Prentice R, et al.; for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80
  • Rossouw JE, Prentice RL, Manson JAE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
  • Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335:239;doi:10.1136/bmj.39266.425069.AD
  • The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;360:2001-8
  • Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 2006;113:5-14
  • Bath PMW, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005;330:342; doi:10.1136/bmj.38331.655347.8F
  • Sare GM, Gray LJ, Bath PMW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008;29:2031-41
  • Salpeter SR, Walsh JME, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women. A meta-analysis. J Gen Intern Med 2004;19:791-804
  • Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21:363-6
  • Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors. A randomized controlled trial. Cancer 1999;86:1013-18
  • Harman SM, Brinton EA, Cedars M, et al. KEEPS: the Kronos Early Estrogen Prevention study. Climacteric 2005;8:3-12
  • Hodis HN. ELITE trial: Early versus Late Intervention with Estradiol. Available from: www.clinicaltrials.gov/show/NCT00114517 [Last accessed 15 March 2009]
  • Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-21
  • Behavioral Risk Factor Surveillance System – Web Enabled Analysis Tool. Available from: http://apps.nccd.cdc.gov/s_broker/htmsql.exe/weat/Select_Year.hsql?Analysis=freq&Title=Cross%20Tabulation [Last accessed 19 March 2009]
  • Stefanick ML, Cochrane BB, Hsia J, et al. The Women's Health Initiative Postmenopausal Hormone Trials: overview and baseline characteristics of participants. Ann Epidemiol 2003;13:S78-86
  • Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US Adults. Diabetes Care 2004;27:2444-9
  • Salpeter SR, Buckley NS, Liu H, et al. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009;122:42-52
  • Hutton JD, Jacobs HS, Murray MA, James VH. Relation between plasma oestrone and oestradiol and climacteric symptoms. Lancet 1978;1:678-81
  • Gast GCM, Grobbee DE, Pop VJM, et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008;51:1492-8
  • Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-93
  • Kok HS, van Asselt KM, vander Schouw YT, et al. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol 2006;47:1976-83
  • Depypere HT, Tummers P, De Bacquer D, et al. Number of women needed in a prospective trial to prove potential cardiovascular benefit of hormone replacement therapy. Climacteric 2007;10:238-43
  • Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy. Findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999;282:2012-18
  • Daviglus ML, Liu K, Pirzada A, et al. Favorable cardiovascular risk profile in middle age and health-related quality of life in older age. Arch Intern Med 2003;163:2460-8
  • Chlebowski RR, Hendrix SL, Langer RD, et al.; for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53
  • Ritenbaugh C, Stanford JL, Wu LL, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative Randomized Clinical Trial. Cancer Epidemiol Biomarkers Prev 2008;17:2609-18
  • Chlebowski RT, Wactawski-Wende J, Ritenbaugh C: for the Women's Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991-1004
  • Jackson RD, Wactawski-Wende J, LaCroix AZ, et al: for the Women's Health Initiative Investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Trial. J Bone Miner Res 2006;21:817-28
  • Cauley JA, Robbins J, Chen Z, et al: for the Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative Randomized Trial. JAMA 2003;290:1729-38

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.